- Home
- NNY vs VTYX Comparison
NNY vs VTYX Comparison
Compare NNY & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNY
- VTYX
- Stock Information
- Founded
- NNY 1987
- VTYX 2018
- Country
- NNY United States
- VTYX United States
- Employees
- NNY N/A
- VTYX N/A
- Industry
- NNY Investment Managers
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- NNY Finance
- VTYX Health Care
- Exchange
- NNY Nasdaq
- VTYX Nasdaq
- Market Cap
- NNY 153.2M
- VTYX 154.9M
- IPO Year
- NNY N/A
- VTYX 2021
- Fundamental
- Price
- NNY $7.99
- VTYX $3.18
- Analyst Decision
- NNY
- VTYX Buy
- Analyst Count
- NNY 0
- VTYX 4
- Target Price
- NNY N/A
- VTYX $11.33
- AVG Volume (30 Days)
- NNY 50.9K
- VTYX 1.7M
- Earning Date
- NNY 01-01-0001
- VTYX 08-07-2025
- Dividend Yield
- NNY 4.04%
- VTYX N/A
- EPS Growth
- NNY N/A
- VTYX N/A
- EPS
- NNY N/A
- VTYX N/A
- Revenue
- NNY N/A
- VTYX N/A
- Revenue This Year
- NNY N/A
- VTYX N/A
- Revenue Next Year
- NNY N/A
- VTYX N/A
- P/E Ratio
- NNY N/A
- VTYX N/A
- Revenue Growth
- NNY N/A
- VTYX N/A
- 52 Week Low
- NNY $7.58
- VTYX $0.78
- 52 Week High
- NNY $8.87
- VTYX $3.39
- Technical
- Relative Strength Index (RSI)
- NNY 37.77
- VTYX 66.17
- Support Level
- NNY $7.99
- VTYX $2.88
- Resistance Level
- NNY $8.13
- VTYX $3.30
- Average True Range (ATR)
- NNY 0.06
- VTYX 0.22
- MACD
- NNY -0.00
- VTYX 0.03
- Stochastic Oscillator
- NNY 12.50
- VTYX 87.02
About NNY Nuveen New York Municipal Value Fund
Nuveen New York Municipal Value Fund Inc is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from both regular federal and New York state income taxes, by investing in a portfolio of municipal obligations issued by state and local government authorities within the state of New York or certain U.S. territories.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.